Key result
Dexmedetomidine added to routine anesthesia in patients with Stanford type-A aortic dissection reduced perioperative markers of myocardial injury, inflammation, and oxidative stress (all P < 0.05).
Why the study?
The protective effect and mechanism of dexmedetomidine on perioperative myocardial injury in patients with Stanford type-A aortic dissection remained to be investigated.
Does dexmedetomidine reduce perioperative myocardial injury in patients with Stanford type-A aortic dissection?
RCT (n=86)
Randomly divided
Does dexmedetomidine reduce perioperative myocardial injury in patients with Stanford type-A aortic dissection?
p-value: p=< 0.05
Dexmedetomidine added to routine anesthesia may alleviate perioperative myocardial injury in patients undergoing surgery for Stanford type-A aortic dissection by reducing inflammation and oxidative stress.
Dexmedetomidine may attenuate perioperative myocardial injury in type A aortic dissection repair; extends RCT evidence for its anti-inflammatory effects in cardiac surgery.
OBJECTIVE: To investigate the protective effect and mechanism of dexmedetomidine (Dex) on perioperative myocardial injury in patients with Stanford type-A aortic dissection (AD). METHODS: Eighty-six patients with Stanford type-A AD were randomly divided into Dex and control groups, with 43 cases in each group. During the surgery, the control group received the routine anesthesia, and the Dex group received Dex treatment based on routine anesthesia. The heart rate (HR) and mean arterial pressure (MAP) were recorded before Dex loading (t0), 10 min after Dex loading (t1), at the skin incision (t2), sternum sawing (t3), before cardiopulmonary bypass (t4), at the extubation (t5), and at end of surgery (t6). The blood indexes were determined before anesthesia induction (T0) and postoperatively after 12h (T1), 24h (T2), 48h (T3), and 72h (T4). RESULTS: At t2 and t3, the HR and MAP in the Dex group were lower than in the control group (P < 0.05). Compared with the control group, in the Dex group at T1, T2, and T3, the serum creatine kinase-MB, cardiac troponin-I, C-reactive protein, and tumor necrosis factor-α levels were decreased, and the interleukin-10 level, the serum total superoxide dismutase, and total anti-oxidant capability increased, while the myeloperoxidase and malondialdehyde levels decreased (all P < 0.05). CONCLUSIONS: Dex treatment may alleviate perioperative myocardial injury in patients with Stanford type-A AD by resisting inflammatory response and oxidative stress.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2020) conducted an RCT in Stanford type-A aortic dissection (n=86). Dexmedetomidine vs. Routine anesthesia was evaluated on Perioperative myocardial injury markers (CK-MB, cTnI, inflammatory and oxidative stress markers) (p=< 0.05). Dexmedetomidine added to routine anesthesia in patients with Stanford type-A aortic dissection reduced perioperative markers of myocardial injury, inflammation, and oxidative stress (all P < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: